Studying the genetics, cell biology and immunology of Cutaneous T-cell Lymphoma (CTCL).
Genomics and Epigenomics in CTCL:
Identifying the pathogenetic mutations in familial CTCL.
MicroRNA profiling of early and advance MF (the most common forms of CTCL), and the role of specific onco-mir in the progression of MF.
RNA editing in the lymphoma cells of patients with Sezary syndrome- the leukemic version of CTCL.
Immune profile of CTCL:
Characterizing the immunologic profile of the malignant and reactive lymphocytes in MF lesions.
Drugs screening and new treatments for CTCL:
We found a new histone deacetylase inhibitory (HDACI) with selective activity on CTCL cell lines- to be tested further in a CTCL mouse model, and its mode of action.
New approach for treating CTCL- combination of HDACI with DNA damage inducing agents.
Other skin diseases
Identifying the pathogenetic mutations in unique families with psoriasis.